Animal models are crucial for improving our understanding of human pathogenesis,
enabling researchers to identify therapeutic targets and test novel drugs. In the current …

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver diseases ranging from
simple steatosis to non-alcoholic steatohepatitis, fibrosis, cirrhosis, and/or hepatocellular …

Background & aims In advanced chronic liver disease (ACLD), deregulated hepatic
necroinflammatory processes play a key role in the development of liver microvascular …

The prevalence of non-alcoholic fatty liver disease (NAFLD) increases year by year, and as
a consequence, NAFLD has become one of the most prevalent liver diseases worldwide …

Semaglutide, a glucagon-like peptide-1 receptor agonist, is an antidiabetic medication that
has recently been approved for the treatment of obesity as well. Semaglutide is postulated to …

Obesity is the primary risk factor for the pathogenesis of non-alcoholic fatty liver disease
(NAFLD), the worldwide prevalence of which continues to increase dramatically. The liver …

Portal hypertension (PH) is the most common non-neoplastic complication of chronic liver
disease, determining clinical complications that lead to death or liver transplantation. PH …

Liver sinusoidal endothelial cells have a gatekeeper function in liver homeostasis by
permitting substrates from the bloodstream into the space of Disse and regulating hepatic …

Metabolic‐associated steatotic liver disease (MASLD) encompasses a wide spectrum of
metabolic conditions associated with an excess of fat accumulation in the liver, ranging from …

Nonalcoholic fatty liver disease (NAFLD) is the leading liver chronic disease featuring
hepatic steatosis. Mitochondrial β-oxidation participates in the derangement of lipid …